Cargando…

470 Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013)

Detalles Bibliográficos
Autores principales:	Mendes, Rodrigo E., Sader, Helio S., Flamm, Robert K., Farrell, David J., Jones, Ronald N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782286/ http://dx.doi.org/10.1093/ofid/ofu052.336

Ejemplares similares

811 Antimicrobial activity of ceftaroline tested against respiratory tract infection (RTI) pathogens isolated from USA medical centers in 2013
por: Sader, Helio S., et al.
Publicado: (2014)

247 Antimicrobial Activity of Ceftolozane/Tazobactam Tested against Gram-negative Bacterial Isolates from Hospitalized Patients with Pneumonia in United States Hospitals (2013)
por: Farrell, David J., et al.
Publicado: (2014)

475 Telavancin (TLV) In vitro Activity Tested Against a USA Collection of Methicillin-resistant Staphylococcus aureus (MRSA), Including a Multidrug-resistant (MDR) Subset (2011-2013)
por: Mendes, Rodrigo E., et al.
Publicado: (2014)

729 Activity of Ceftaroline and Comparator Agents Tested against Staphylococcus aureus from Patients with Bacteremia in United States (USA) Medical Centers (2009-2013)
por: Sader, Helio S., et al.
Publicado: (2014)

1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Corey, Ralph, et al.
Publicado: (2014)

250 Ceftazidime-avibactam Activity Tested Against a Large Collection of Enterobacteriaceae Isolates Collected in United States (USA) Hospitals in the 2011-2013 Period, Including Organisms Producing KPC- and CTX-M-variants
por: Castanheira, Mariana, et al.
Publicado: (2014)

Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

413 In Vitro Activity of Tigecycline against Commonly-Isolated Pathogens of Skin and Skin Structure Infections in the United States – TEST 2011-2013
por: Hackel, Meredith, et al.
Publicado: (2014)

1583. Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

410 Tracking Linezolid Antimicrobial Activity and Resistance in North America: Results from LEADER 2013 Program
por: Flamm, Robert K., et al.
Publicado: (2014)

357 Epidemiology of Carbapenem-Resistant Gram-Negative Bacilli in Georgia, Minnesota, and Oregon – 2012
por: Guh, Alice, et al.
Publicado: (2014)

1155 Origin of the dengue virus outbreak in Martin County, Florida, USA 2013
por: Ramgopal, Moti N., et al.
Publicado: (2014)

155 Implementation of a national surveillance program for antimicrobial use, Colombia 2012-2013
por: Moreno, Carlos Arturo Alvarez, et al.
Publicado: (2014)

1136 Surveillance of Acute Flaccid Paralysis (AFP) in the Republic of Korea during 2012-2013
por: Yoon, Young-Sil, et al.
Publicado: (2014)

412 In vitro Activity of Key Antimicrobial Agents Against Bacterial Isolates From Intra-abdominal (IAI) and Skin and Wound (SW) Infections: Europe 2004-2013
por: Hoban, Daryl, et al.
Publicado: (2014)

880 Incidence rates of ventilator-associated events and ventilator-associated pneumonia in the National Healthcare Safety Network, 2012-2013
por: Magill, Shelley S., et al.
Publicado: (2014)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

466 Skin lesions in febrile neutropenic patients
por: Yemisen, Mucahit, et al.
Publicado: (2014)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

264 Results of the Surveillance of Tedizolid Activity and Resistance (STAR) Program: In Vitro Susceptibility of Gram-Positive Clinical Isolates Collected in 2013 From the United States
por: Bien, Paul, et al.
Publicado: (2014)

674 Comparison of the Microbiology and Antibiotic Treatment between Diabetic and Non-Diabetic Patients Hospitalized with Acute Bacterial Skin and Skin Structure Infection
por: Jenkins, Timothy, et al.
Publicado: (2014)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

769 Short Duration of Antimicrobial Treatment for Acute Cholangitis with Bacteremia due to Gram-negative Bacilli after the Publication of the Updated Tokyo Guidelines 2013 (TG13)
por: Uno, Shunsuke, et al.
Publicado: (2014)

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

682 Microbiology and Antibiotic Treatment among Injection Drug Users and Non-Injection Drug Users Hospitalized with Acute Bacterial Skin and Skin Structure Infection
por: Jenkins, Timothy, et al.
Publicado: (2014)

262 Effect of NSAID/Corticosteroid Use on the Efficacy of Tedizolid in Acute Bacterial Skin and Skin Structure Infections: Pooled Data From the Phase 3 ESTABLISH-1 and ESTABLISH-2 Studies
por: Sandison, Taylor, et al.
Publicado: (2014)

282 Epidemiology of Skin and Soft-Tissue Infections in US Army Trainees at Fort Benning
por: Ellis, Michael, et al.
Publicado: (2014)

1294 Skin Microbiota Contamination Causes False Positive QuantiFERON-TB Results
por: Gaur, Rajiv
Publicado: (2014)

678 Ceftaroline vs Vancomycin in Treatment for Skin and Soft Tissue Infections (SSTI) in Obese Patients
por: Nguyen, Hao, et al.
Publicado: (2014)

712 Gram-negative associated Ventricular Assist Device infections
por: Patel, Ami, et al.
Publicado: (2014)

714 Gram Negative Bacteremia: Are Shorter Courses of Antimicrobial Therapy Feasible?
por: Swamy, Siddharth, et al.
Publicado: (2014)

680 Predictors of Recurrent Staphylococcus aureus Skin Infection After Treatment: Host, Behavioral, and Pathogen Level Factors
por: Miller, Loren, et al.
Publicado: (2014)

1734 Cyclosporiasis 2013: Collaborative Outbreak Investigations
por: Gensheimer, Kathleen, et al.
Publicado: (2014)

715 Impact of Fluoroquinolone Resistance on Community-Onset Gram-Negative Bloodstream Infections
por: Brigmon, Matthew, et al.
Publicado: (2014)

489 Accuracy of Clinicians' Empiric Treatment Choices for Resistant Gram-Negative Uropathogens
por: Linsenmeyer, Katherine, et al.
Publicado: (2014)

456 Infectious Myositis Secondary to Multidrug-Resistant Gram Negative Rods in Cancer Patients
por: Mori, Nobuyoshi, et al.
Publicado: (2014)

165 Integrating a Rapid Diagnostic Test and Antimicrobial Stewardship: Optimizing Discharge Antibiotics in Skin and Soft Tissue Infections (SSTI)
por: Yu, Diana, et al.
Publicado: (2014)

366 The Impact of Bathing Hospitalized Dependent Patients with Disposable Washcloths Instead of Traditional Bath Basins on Infection Rates and Skin Condition
por: Haider, Samran, et al.
Publicado: (2014)

1293 Clinical Characteristics of Botulism in the United States, 2002–2012
por: Rao, Agam K., et al.
Publicado: (2014)

252 S-649266, a Novel Siderophore Cephalosporin: In vitro activity against Gram-negative bacteria
por: Tsuji, Masakatsu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ado8a7dd3ujve7nou46pcm6qne